BioAge Labs (BIOA) Preferred Stock Liabilities (2023 - 2024)

BioAge Labs (BIOA) posted Preferred Stock Liabilities of $342.8 million for Q2 2024, little changed sequentially from $342.8 million in Q1 2024.

BioAge Labs (BIOA) Preferred Stock Liabilities (2023 - 2024) Analysis & Trends

BioAge Labs has reported Preferred Stock Liabilities for 2 years, with the latest figure at $342.8 million in Q2 2024.

Quarterly Preferred Stock Liabilities changed N/A year-over-year to $342.8 million in Q2 2024, while the trailing twelve-month figure through Jun 2024 was $342.8 million (changed N/A YoY) and the FY2023 annual result came in at $18.2 million, changed N/A from the prior year.
Preferred Stock Liabilities was little changed at $342.8 million in Q2 2024 per BIOA's latest filing, from $342.8 million in the prior quarter.
Over five years, Preferred Stock Liabilities peaked at $342.8 million in Q1 2024 and troughed at $18.2 million in Q4 2023.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Preferred Stock Liabilities (Qtr)
1	Haleon	43.91 Bn	42.95 Bn	-	-
2	Teva Pharmaceutical Industries	42.98 Bn	39.32 Bn	2.15 Bn	-
3	Zoetis	31.53 Bn	29.86 Bn	1.05 Bn	-
4	Takeda Pharmaceutical	28.61 Bn	22.81 Bn	5.10 Bn	-
5	United Therapeutics	22.16 Bn	19.49 Bn	683.80 Mn	-
6	Viatris	18.74 Bn	17.85 Bn	1.46 Bn	-
7	Neurocrine Biosciences	15.51 Bn	15.12 Bn	935.80 Mn	-
8	Elanco Animal Health	11.76 Bn	11.23 Bn	798.00 Mn	-
9	Dr Reddys Laboratories	10.12 Bn	9.95 Bn	-	-
10	BioAge Labs	436.28 Mn	436.28 Mn	-14.23 Mn	-

Download Data